Adults with Down Syndrome in Randomized Clinical Trials Targeting Prevention of Alzheimer's Disease

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2021 Dec 7

PMID 34873819

Citations 3

Authors

Wayne Silverman

Sharon J Krinsky-McHale

Warren B Zigman

Nicole Schupf

Affiliations

Soon will be listed here.

Abstract

Introduction: Adults with Down syndrome, the largest population genetically predisposed to high risk for Alzheimer's disease (AD), are ideally suited participants for clinical trials targeting prevention. Critically important considerations for the design of such trials include appropriate selection of participants, outcome measures, and duration of follow-up.

Methods: Archived data for 12 measures of performance over a 3-year period were analyzed for 185 adults with Down syndrome 36 years of age and older with presumptive preclinical AD.

Results: Declines over 3 years were not observed prior to 46 years of age. However, declines were observed at older ages, increasing monotonically for groups aged 46-49, 50-55, and >55, as did incidence of prodromal AD and dementia.

Discussion: Significant decline over a 2- to 3-year period for a prospective placebo group of adults with Down syndrome enrolled in clinical prevention trials can only be expected when inclusion is limited to adults older than 45 years of age.

Citing Articles

Physical Activity and Cognitive Impairment in a Group of Adults with Down Syndrome from North-Eastern Romania.

Lefter N, Abdulan I, Mastaleru A, Leon M, Rusu C J Clin Med. 2024; 13(19).

PMID: 39407889 PMC: 11478143. DOI: 10.3390/jcm13195829.

Non-Invasive Drug Delivery across the Blood-Brain Barrier: A Prospective Analysis.

Niazi S Pharmaceutics. 2023; 15(11).

PMID: 38004577 PMC: 10674293. DOI: 10.3390/pharmaceutics15112599.

Individualized estimated years from onset of Alzheimer's disease- related decline for adults with Down syndrome.

Silverman W, Krinsky-McHale S, Kovacs C, Lee J, Listwan T, Pang D Alzheimers Dement (Amst). 2023; 15(2):e12444.

PMID: 37389223 PMC: 10300244. DOI: 10.1002/dad2.12444.

References

Handen B, Lott I, Christian B, Schupf N, OBryant S, Mapstone M . The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology. Alzheimers Dement (Amst). 2020; 12(1):e12065. PMC: 7396809. DOI: 10.1002/dad2.12065. View

Silverman W, Schupf N, Zigman W, Devenny D, Miezejeski C, Schubert R . Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard. 2004; 109(2):111-25. DOI: 10.1352/0895-8017(2004)109<111:DIAWMR>2.0.CO;2. View

Graham W, Bonito-Oliva A, Sakmar T . Update on Alzheimer's Disease Therapy and Prevention Strategies. Annu Rev Med. 2017; 68:413-430. DOI: 10.1146/annurev-med-042915-103753. View

Silverman W, Krinsky-McHale S, Lai F, Rosas H, Hom C, Doran E . Evaluation of the National Task Group-Early Detection Screen for Dementia: Sensitivity to 'mild cognitive impairment' in adults with Down syndrome. J Appl Res Intellect Disabil. 2020; 34(3):905-915. PMC: 8356176. DOI: 10.1111/jar.12849. View

Zigman W, Lott I . Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev. 2007; 13(3):237-46. DOI: 10.1002/mrdd.20163. View

Haxby J . Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in non-demented old adults. J Ment Defic Res. 1989; 33 ( Pt 3):193-210. DOI: 10.1111/j.1365-2788.1989.tb01467.x. View

Evenhuis H . Evaluation of a screening instrument for dementia in ageing mentally retarded persons. J Intellect Disabil Res. 1992; 36 ( Pt 4):337-47. DOI: 10.1111/j.1365-2788.1992.tb00532.x. View

Krinsky-McHale S, Devenny D, Kittler P, Silverman W . Selective attention deficits associated with mild cognitive impairment and early stage Alzheimer's disease in adults with Down syndrome. Am J Ment Retard. 2008; 113(5):369-86. DOI: 10.1352/2008.113:369-386. View

Hartley S, Handen B, Devenny D, Hardison R, Mihaila I, Price J . Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain. 2014; 137(Pt 9):2556-63. PMC: 4189400. DOI: 10.1093/brain/awu173. View

10.

Evenhuis H . The natural history of dementia in ageing people with intellectual disability. J Intellect Disabil Res. 1997; 41 ( Pt 1):92-6. DOI: 10.1111/j.1365-2788.1997.tb00682.x. View

11.

Hartley S, Handen B, Devenny D, Mihaila I, Hardison R, Lao P . Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome. Neurobiol Aging. 2017; 58:68-76. PMC: 5581712. DOI: 10.1016/j.neurobiolaging.2017.05.019. View

12.

Albert M, Cohen C . The Test for Severe Impairment: an instrument for the assessment of patients with severe cognitive dysfunction. J Am Geriatr Soc. 1992; 40(5):449-53. DOI: 10.1111/j.1532-5415.1992.tb02009.x. View

13.

Krinsky-McHale S, Zigman W, Lee J, Schupf N, Pang D, Listwan T . Promising outcome measures of early Alzheimer's dementia in adults with Down syndrome. Alzheimers Dement (Amst). 2020; 12(1):e12044. PMC: 7335903. DOI: 10.1002/dad2.12044. View

14.

. 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020; . DOI: 10.1002/alz.12068. View

15.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

16.

Krinsky-McHale S, Devenny D, Silverman W . Changes in explicit memory associated with early dementia in adults with Down's syndrome. J Intellect Disabil Res. 2002; 46(Pt 3):198-208. DOI: 10.1046/j.1365-2788.2002.00365.x. View

17.

Bayen E, Possin K, Chen Y, Cleret de Langavant L, Yaffe K . Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome. JAMA Neurol. 2018; 75(11):1399-1406. PMC: 6248113. DOI: 10.1001/jamaneurol.2018.2210. View

18.

Deb S, Hare M, Prior L, Bhaumik S . Dementia screening questionnaire for individuals with intellectual disabilities. Br J Psychiatry. 2007; 190:440-4. DOI: 10.1192/bjp.bp.106.024984. View

19.

Hithersay R, Baksh R, Startin C, Wijeratne P, Hamburg S, Carter B . Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome. Alzheimers Dement. 2020; 17(4):595-604. DOI: 10.1002/alz.12222. View